Key Insights on Gross Profit: Corcept Therapeutics Incorporated vs Evotec SE

Biotech Giants: Corcept vs. Evotec's Profit Growth

__timestampCorcept Therapeutics IncorporatedEvotec SE
Wednesday, January 1, 20142566900029378000
Thursday, January 1, 20154892500037987000
Friday, January 1, 20167926300058554000
Sunday, January 1, 201715564700082568000
Monday, January 1, 2018246032000112016000
Tuesday, January 1, 2019300982000132891000
Wednesday, January 1, 2020348292000125743000
Friday, January 1, 2021360697000151543000
Saturday, January 1, 2022396473000174065000
Sunday, January 1, 2023475894000175051000
Loading chart...

Unlocking the unknown

A Decade of Growth: Corcept Therapeutics vs. Evotec SE

In the competitive landscape of biotechnology, Corcept Therapeutics Incorporated and Evotec SE have shown remarkable trajectories in gross profit over the past decade. From 2014 to 2023, Corcept Therapeutics has experienced a staggering growth of over 1,750%, starting from a modest $25.7 million to an impressive $475.9 million. This growth underscores Corcept's strategic advancements and market positioning.

Meanwhile, Evotec SE has also demonstrated a commendable increase, with its gross profit rising by nearly 500% during the same period, from $29.4 million to $175.1 million. This consistent upward trend highlights Evotec's robust business model and its ability to capitalize on market opportunities.

These insights not only reflect the companies' financial health but also their potential for future growth in the ever-evolving biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025